Assessing Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III And Phase II Trial Results

Simply Wall St.06-02

Summit Therapeutics (SMMT) is back in focus after reporting positive overall survival data from its Phase III HARMONi-6 trial in advanced squamous NSCLC, along with strong response rates in a Phase II...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640967939?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-02 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640967939","market":"nz","top_or_hot":-1,"title":"Assessing Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III And Phase II Trial Results","media":"Simply Wall St.","content":"<div>\n<p>Summit Therapeutics (SMMT) is back in focus after reporting positive overall survival data from its Phase III HARMONi-6 trial in advanced squamous NSCLC, along with strong response rates in a Phase II...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/assessing-summit-therapeutics-smmt-valuation-after-new-ivone\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III And Phase II Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III And Phase II Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-02 04:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/assessing-summit-therapeutics-smmt-valuation-after-new-ivone><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit Therapeutics (SMMT) is back in focus after reporting positive overall survival data from its Phase III HARMONi-6 trial in advanced squamous NSCLC, along with strong response rates in a Phase II...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/assessing-summit-therapeutics-smmt-valuation-after-new-ivone\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/assessing-summit-therapeutics-smmt-valuation-after-new-ivone","article_id":"2640967939","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/assessing-summit-therapeutics-smmt-valuation-after-new-ivone","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640967939","pubTimestamp":1780345266,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Summit Therapeutics (SMMT) is back in focus after reporting positive overall survival data from its Phase III HARMONi-6 trial in advanced squamous NSCLC, along with strong response rates in a Phase II metastatic colorectal cancer study.\nSee our latest analysis for Summit Therapeutics.\nThose new ivonescimab data arrive after a steady run in the stock, with a 90 day share price return of 16.08% and a very large 3 year total shareholder return, suggesting momentum has been building around...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"III":"信息服务","SMMT":"Summit Therapeutics PLC","BK4139":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4134":"信息科技咨询与其它服务"},"translate_title":"评估新ivonescimab III期和II期试验结果后Summit Therapeutics(SMMT)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1.5,"III":1.5},"content_text":"Summit Therapeutics (SMMT) is back in focus after reporting positive overall survival data from its Phase III HARMONi-6 trial in advanced squamous NSCLC, along with strong response rates in a Phase II metastatic colorectal cancer study. See our latest analysis for Summit Therapeutics. Those new ivonescimab data arrive after a steady run in the stock, with a 90 day share price return of 16.08% and a very large 3 year total shareholder return, suggesting momentum has been building around Summit’s progress. If this kind of clinical progress has your attention, it can be useful to see what else is moving in related areas, starting with 39 healthcare AI stocks With shares up 16.08% over 90 days but still trading well below the average analyst price target, the key question now is whether Summit is still undervalued or if the stock already reflects expectations for future growth. AdvertisementMost Popular Narrative: 39.9% Undervalued Summit Therapeutics last closed at $17.54, while the most followed narrative anchors fair value closer to $29.18. This sets up a wide valuation gap driven by late stage oncology ambitions.  The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.  Read the complete narrative. Want to see what kind of revenue build these trials are aiming for, and how margins and future P/E assumptions connect that story to a higher fair value? The narrative lays out a detailed path from zero revenue today to a large top line, rising profitability and a rich valuation multiple that has to hold together for the math to work. Result: Fair Value of $29.18 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story still hinges on a single lead asset and heavy R&D spend, so any regulatory setback or slower trial progress could quickly challenge that undervalued case. Find out about the key risks to this Summit Therapeutics narrative. Next Steps If this mix of excitement and caution around Summit resonates, consider it a prompt to act quickly and evaluate the thesis using your own analysis of real numbers and scenario ranges. To weigh both sides clearly, review the 2 key rewards and 3 important warning signs. Looking for more investment ideas? If Summit has sharpened your focus, do not stop here. Broaden your watchlist now so you are not relying on a single story.  Target potential upside by scanning companies that combine stronger fundamentals with attractive pricing using the 46 high quality undervalued stocks. Prioritise resilience by checking out the 64 resilient stocks with low risk scores and see which stocks carry lower risk scores while still offering meaningful exposure. Hunt for overlooked opportunities through the screener containing 22 high quality undiscovered gems and spot quality businesses that many investors might not be watching yet.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640967939","isCrawlerRequest":true}